NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.87 +4.25%

+$0.29 today

Market cap
$69.12M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.23M

Average 0.18M

NRXS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

NeurAxis, Inc.AMEX: NRXS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$1.72M, compared with -$2.27M a year earlier. Trailing-twelve-month EBITDA was -$7.12M.

Context

  • EBITDA amounted to 214.8% of revenue in FY2025, down 79.4 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$5.38M (+29.9%) for the fiscal year ending Dec 2026, a step up from the +3.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.72M-3.8% QoQ
Last fiscal yearDec 2025
-$7.67M+3.0% YoY
LTMMar 2026
-$7.12M+12.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.3%-147.5%-171.8 pp
1 year+3.0%+29.9%+26.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(7.67M) USD
Year-over-year change
+3.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NRXS compares with its peers on the latest reported figures

  • NRXS's LTM Mar 2026 EBITDA of -$7.12M is the highest of the 4 companies compared; the peer median is -$28.06M.
  • Its year-over-year change of +12.3% is the 2nd highest of 4, against a peer median of +2.5%.
  • EBITDA amounts to 166.2% of revenue for NRXS, versus a peer median of 3270.4%.
NRXS Competitors Peer median
EBITDA for NRXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRXSNeurAxis, Inc.LTM Mar 2026-$7.12M +12.3%—166.2%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025-$14.32M +2.5%——
RLYBRallybio CorporationLTM Mar 2026-$28.06M +44.2%—3270.4%
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$394.35M -3608.6%——
Peer median (excluding NRXS) -$28.06M+2.5%—3270.4%

Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M2.68M2.46M2.69M3.57M
Cost of Revenue467.66K297.06K303.35K362K562.92K
Gross Profit2.25M2.39M2.16M2.32M3.01M
Gross Margin82.8%88.9%87.7%86.5%84.2%
Research & Development203.41K225.61K169.32K206.11K493.61K
Selling, General & Admin5.02M5.53M8.65M9.27M10.34M
Operating Expenses5.22M5.76M8.82M9.48M10.84M
Depreciation & Amortization36.71K37.13K40.73K37.83K59.5K
EBITDA(2.95M)(4.33M)(9.23M)(7.9M)(7.67M)
EBITDA Margin-108.6%-161.1%-375.1%-294.2%-214.8%
Operating Income(2.97M)(3.37M)(6.66M)(7.16M)(7.83M)
Operating Margin-109.1%-125.6%-270.9%-266.5%-219.4%
Interest Income0(2.32M)(2.77K)00
Interest Expense36.93K417.6K5.36M300.72K73.97K
Other Income / Expenses(58K)(1.41M)(7.96M)(1.08M)29.35K
Income Before Tax(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Pre-Tax Margin-111.3%-178.0%-594.6%-306.8%-218.5%
Income Tax Expense00000
Net Income(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Net Margin-111.3%-178.0%-594.6%-306.8%-218.5%
EPS (Basic)(0.62)(0.57)(2.32)(1.22)(0.95)
EPS (Diluted)(0.62)(0.78)(2.32)(1.22)(0.95)
Weighted Avg Shares5.38M8.41M6.3M6.92M9.08M
Weighted Avg Shares (Diluted)5.38M8.41M6.3M6.92M9.08M

NeurAxis, Inc.

AMEX:NRXS

Intrinsic Alpha fair value

Locked

Current Price

$4.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.